Peer-reviewed veterinary case report
Targeted maduramicin nanotherapy for canine mammary tumors
By Song, Xinhao et al.·Published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2024·Nanjing Agricultural University, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Maduramicin-guided nanotherapy: A polymeric micelles for targeted drug delivery in canine mammary tumors.
- Species:
- dog
Plain-English summary
A study looked at a new treatment for canine mammary tumors (CMT) in dogs, which can be very serious and lead to a poor quality of life. Researchers developed a special delivery system using maduramicin (MAD) combined with polymeric micelles to improve its effectiveness and reduce side effects. This new treatment showed better results in stopping tumor growth and preventing the spread of cancer compared to the standard method. The findings suggest that this targeted therapy could be a promising option for dogs suffering from CMT.
People also search for: dog mammary tumor treatment · maduramicin for canine cancer · canine breast cancer therapy
Abstract
Canine mammary tumors (CMT) can severely compromise the life quality of the affected dogs through local recurrence, distant metastases and ultimately succumb to death. Recently, more attention has been given to the potential antimetastatic effect of maduramicin (MAD) on breast cancer. However, its poor aqueous solubility and toxicity to normal tissues limit its clinical application. Therefore, to address the drawbacks of MAD and enhance its anticancer and antimetastatic effects, MAD-loaded TPGS polymeric micelles (MAD-TPGS) were prepared by a thin-film hydration technique. The optimized MAD-TPGS exhibited excellent size distribution, stability and improved water solubility. Cellular uptake assays showed that TPGS polymer micelles could enhance drug internalization. Moreover, TPGS synergistically improved the cytotoxicity of MAD by targeting mitochondrial organelles, improving reactive oxygen species levels and reducing the mitochondrial transmembrane potential. More importantly, MAD-TPGS significantly impeded the metastasis of tumor cells. In vivo results further confirmed that, in addition to exhibiting excellent biocompatibility, MAD-TPGS exhibited greater antitumor efficacy than free MAD. Interestingly, MAD-TPGS displayed superior suppression of CMT metastasis via tail vein injection compared to oral administration, indicating its suitability for intravenous delivery. Overall, MAD-TPGS could be applied as a potential antimetastatic cancer agent for CMT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38150878/